In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Wellington Management Group LLP | 9.54M | $355.0M | 12.16% | +983.2K | 2026-06-30 |
| BlackRock, Inc. | 7.00M | $260.0M | 8.92% | +1.63M | 2026-06-30 |
| Kynam Capital Management, LP | 5.32M | $198.0M | 6.78% | -517.7K | 2026-06-30 |
| Price T Rowe Associates Inc | 4.69M | $174.0M | 5.97% | +2.60M | 2026-06-30 |
| State Street Corp | 3.90M | $145.0M | 4.97% | +1.10M | 2026-06-30 |
| FMR LLC | 3.72M | $138.0M | 4.74% | -26.2K | 2026-06-30 |
| Vanguard Capital Management LLC | 3.46M | $128.0M | 4.41% | +503.9K | 2026-06-30 |
| Deep Track Capital, LP | 2.94M | $109.0M | 3.74% | +1.66M | 2026-06-30 |
| Logos Global Management LP | 2.10M | $78.0M | 2.68% | +1.65M | 2026-06-30 |
| Geode Capital Management, LLC | 2.02M | $75.0M | 2.58% | +334.2K | 2026-06-30 |
